Cyfuse Biomedical K.k. (4892.T) Stock

4892.T logo

Cyfuse Biomedical K.k.

4892.TJapan
Healthcare

Company profile

Cyfuse Biomedical K.k. reported revenue of 231.00 million JPY for fiscal year 2025, and a net loss of 763.84 million JPY. That is a net profit margin of -330.7% for fiscal year 2025. Our analysis of its filings shows revenue growing from 61.11 million JPY in fiscal year 2023 to 231.00 million JPY in fiscal year 2025, 94.4% a year on average. Cyfuse Biomedical K.k. reports about 23 full-time employees.

What stands out

  • Revenue more than tripled (up 324.3%) in fiscal year 2025, from 54.45 million JPY in fiscal year 2024, after a fall of 10.9% the year before.
  • It reported a net loss in each of its last 4 fiscal years (2022 to 2025), after a profit of 142.91 million JPY in fiscal year 2021.
  • Its net profit margin over the last four reported quarters was -260.7%, against a median of -1.3% for 5 listed companies of similar size in its industry.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Cyfuse Biomedical K.k.

Cyfuse Biomedical K.K. develops, manufactures, and sells regenerative medicine-related products in Japan, Europe, and the United States. The company offers the Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bone, blood vessels, and nerves; regenova, a 3D software that creates 3D data where spheroids shall be mounted; and S-PIKE that develops 3D-structures from cells. It also provides the Human 3D Mini-Liver, an in vitro MASH model that recapitulates human liver functions and predicts efficacy of drugs. Cyfuse Biomedical K.K. was incorporated in 2010 and is headquartered in Minato, Japan.

Leadership

  • Shizuka Akieda — President & Representative Director, 49
  • Masahiro Sanjo — CFO, Director of Business Administration Department & Director, 49
  • Koichi Nakayama M.D., Ph.D. — Co-Founder
  • Norihiko Tokunaga — GM of System Development Department & Director, 49

How much revenue does Cyfuse Biomedical K.k. make?

Cyfuse Biomedical K.k. reported 231.00 million JPY in revenue for fiscal year 2025, up 324.3% from 54.45 million JPY in fiscal year 2024.

What companies are similar to Cyfuse Biomedical K.k.?

Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Japan Tissue Engineering Co., Ltd. (7774.T), JMS Co.,Ltd. (7702.T), Create Medic Co., Ltd. (5187.T), atect corporation (4241.T).

How has Cyfuse Biomedical K.k.'s revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 708.25 million JPY; FY2022, 374.48 million JPY; FY2023, 61.11 million JPY; FY2024, 54.45 million JPY; FY2025, 231.00 million JPY.

Has Cyfuse Biomedical K.k. made a profit in recent years?

Net income by fiscal year: FY2021, 142.91 million JPY; FY2022, a loss of 473.96 million JPY; FY2023, a loss of 589.21 million JPY; FY2024, a loss of 872.24 million JPY; FY2025, a loss of 763.84 million JPY. It reported a net loss in 4 of these 5 years.

Company Information

SectorHealthcare
IndustryVarious Healthcare Equipment Manufacturing
Employees23
HeadquartersMinato, Japan
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
South Tower, Sumitomo Fudosan Tokyo Mita, Minato, 108-6301
Phone
81 3 6435 1885
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Cyfuse Biomedical K.k. (4892.T)”, data as of Jun 30, 2026, https://dataporium.tech/stocks/4892.T

LinkedInLinkedInXXYouTubeYouTube